| Background : Schizophrenia is a chronic,highly relapsing,and disabling psychotic disorder that often begins in young adulthood and has a recurrent fluctuating course.Clinically,with pharmacological treatment remaining at the core.Patients have poor compliance and are easily influenced by the economic,and social environment,and their psychological factors,resulting in omission or unauthorized discontinuation of medication,which is detrimental to the control of the disease and thus leads to poor long-term prognosis.At present,long-acting injections are mainly used in outpatients and inpatients at home and abroad,and fewer observations have been made on community home patients,so this study focuses on the efficacy and adverse effects of intramuscular injection of long-acting injections in community schizophrenia patients.Objective: To investigate the clinical effects and safety of paliperidone palmitate injection in the treatment of schizophrenia and to provide a reference for the medication of schizophrenia patients at home in the communityMethods: All patients with schizophrenia participating in the study were recorded and managed in communities in Shandong Province,and 160 patients who met the enrolment criteria were selected and then grouped into 80 paliperidone palmitate intramuscular injection group(experimental group)and 80 paliperidone extended-release tablet oral group(control group)by random number table method.The patients were divided into two groups by the random number table method.The duration of treatment is 12 months,and all patients are treated before and after treatment with outcome measures such as the Positive and Negative Syndrome Scale(PANSS),the Clinical Global Impression Scale(CGI-S),the selfadministered Medication Satisfaction Scale(Personal with Medication Scale),Hepatorenal Function Index and other outcome measures.Satisfaction with Medication Scale,Personal and Social Performance Scale(PSP),and Hepatic and Renal Function Index.All adverse effects occurring during treatment were observed and recorded.The analysis was performed using SPSS25.0 statistical software.Results:1.A total of 160 patients with schizophrenia were included in the study,including 80 in the experimental group and 80 in the control group;10 patients were screened out in each of the two groups during the experiment,so there were 70 valid patients in each of the two data groups.Overall patient demographics did not differ significantly between the two groups and were comparable(P>0.05).2.PANSS total score: At the time of enrollment,there was no significant difference between the PANSS scale scores of patients in the two groups(P>0.05).After 12 months of treatment,the PANSS scale scores of patients in both groups decreased significantly(P<0.05),and the total PANSS scale scores of patients in the experimental group were significantly lower than those in the control group(P<0.05).3.Clinical efficacy: Calculated by the formula of PANSS subtraction rate,the results showed that 12 people in the control group were cured,23 people were significantly effective,18 people were improved,and 17 people were invalid,with a total effective rate of 75.71%;20 people in the experimental group were cured,33 people were significantly effective,13 people were improved,and 4 people were invalid,with a total effective rate of 94.29%.The difference in total effective rate between the two groups was statistically significant(P<0.05).4.PSP total score: Before treatment,the PSP scale scores of the two groups were not significantly different(P>0.05).After 12 months of treatment,the PSP scale score of the experimental group was significantly higher than the control group(P<0.05),and the PSP scale scores of the two groups were significantly higher(P<0.05).5.CGI-S total score: before treatment,the difference in CGI-S scores between the two groups was not statistically significant(P>0.05).A comparison of CGI-S scores within the post-treatment group showed that they were significantly lower than those obtained before treatment(P<0.05);post-treatment CGI-S scores in the experimental group were significantly lower than those in the post-treatment control group,and the difference was statistically significant(P<0.05).6.Satisfaction scores: no significant difference(P>0.05)was found between the satisfaction scores of the two groups before treatment;after 12 months of treatment,the satisfaction scores of both groups improved significantly(P<0.05);the satisfaction scores of the experimental group were significantly higher than those of the control group after treatment(P<0.05).7.Liver and kidney function indices: Before treatment,there was no significant difference in the liver and kidney function indices between the two groups(P>0.05).After treatment,there was no significant change in the liver and kidney function indices between the two groups,and the difference between the groups was not statistically significant(P>0.05).8.Adverse reactions: various tolerable adverse reactions occurred in different patients during the experiment,but no serious adverse reactions occurred and there was no significant difference in adverse reactions occurring in the two groups(P>0.05).Conclusion:1.Intramuscular paliperidone palmitate injection was superior to oral paliperidone extended-release tablets in terms of efficacy and improvement of social functioning in patients with schizophrenia.2.Family members were more satisfied with intramuscular paliperidone palmitate injection compared with oral paliperidone extended-release tablets.3.The effects of both dosage forms of paliperidone palmitate on patients’ liver and kidney functions were less.4.Both dosage forms of paliperidone palmitate for schizophrenia triggered some tolerable adverse reactions,such as headache,insomnia,vomiting,constipation and tremor,and there was no significant difference in the incidence of triggering adverse reactions. |
PDF Full Text Request